Posted by Michael Wonder on 23 Nov 2020
European Commission approves MenQuadfi, the latest innovation in meningococcal vaccination for individuals 12 months of age and older
23 November 2020 - EC approval based on robust data from seven pivotal Phase 2 and 3 trials involving more than 6,300 individuals aged 12 months and older.
The European Commission has approved MenQuadfi for active immunization of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y.
